Yale researchers discover new technique for identifying common brain disorders

New research from Yale University has provided an innovative approach to scanning brains for common brain disorders, a technique that could shed light on how to diagnose and treat a variety of disorders like Alzheimer’s disease and epilepsy.

The researchers of the study, published July 20 in Science Translational Medicine, combined PET scanning technology with biochemistry to quantify synapses throughout the brain.

Richard Carson, the lead author on the study and a professor of radiology and biochemical imaging at Yale University, and his team created a radioactive tracer that binds with a key protein that is in all synapses across the brain.

They used the imaging method in baboons and humans and confirmed the technique served as a marker for synaptic density.

"This is the first time we have synaptic density measurement in live human beings," Carson said. "Up to now any measurement of synaptic density was postmortem."

In addition to being able to examine the progression of brain disorders, the new method could also lend itself to measuring how pharmaceuticals slow the loss of neurons in the brain. Looking ahead, they plan to launch other studies to examine them.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.